Does post mastectomy radiotherapy reduce loco-regional recurrence rates in all clinical stages of breast cancer following a complete pathological response to neoadjuvant chemotherapy? A systematic review and meta-analysis of the literature

IF 0.4 Q4 ONCOLOGY

Breast Cancer Management Pub Date : 2020-04-15 DOI:10.2217/bmt-2020-0011

Reena Shah, A. Hunter-Smith, Azel Botes, Z. Rayter

引用次数: 1

Abstract

The role of post-mastectomy radiotherapy (PMRT) has not been qualified in contemporary cohorts that have achieved complete pathological response (pCR) following neoadjuvant chemotherapy (NAC). This systematic review evaluated loco-regional recurrence (LRR) rates following PMRT for patients with pCR or pathologically lymph node negative disease (ypN0) after NAC. We identified seven papers that described LRR in 415 patients with pCR following NAC. Pooled analysis demonstrated clear benefit of PMRT on LRR (OR: 0.2 [95% CI: 0.06–0.58; p = 0.003]) and this was most pronounced in stage III/IV disease (OR: 0.12 [95% CI: 0.04–0.44; p = 0.0012]), as well as of benefit in ypN0 disease. PMRT appears to be effective in reducing LRR following pCR or ypN0 in advanced breast cancer but requires further investigation.

查看原文本刊更多论文

在对新辅助化疗有完全病理反应后，乳房切除术后放疗是否降低了癌症所有临床阶段的局部区域复发率？文献的系统综述和荟萃分析

在新辅助化疗（NAC）后获得完全病理反应（pCR）的当代队列中，乳房切除术后放疗（PMRT）的作用尚不明确。本系统综述评估了NAC后pCR或病理性淋巴结阴性疾病（ypN0）患者PMRT后局部区域复发（LRR）率。我们鉴定了7篇论文，描述了415名NAC后pCR患者的LRR。汇总分析表明，PMRT对LRR有明显的益处（OR:0.2[95%CI:0.06–0.58；p=0.003]），这在III/IV期疾病中最为明显（OR:0.12[95%CI:0.04–0.44；p=0.0012]），对ypN0疾病也有益处。在晚期癌症中，在pCR或ypN0后，PMRT似乎能有效降低LRR，但需要进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast Cancer Management ONCOLOGY-

CiteScore

0.60

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Breast Cancer Management (ISSN: 1758-1923) addresses key issues in disease management by exploring the best patient-centered clinical research and presenting this information both directly, as clinical findings, and in practice-oriented formats of direct relevance in the clinic. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Breast Cancer Management provides oncologists and other health professionals with the latest findings and opinions on reducing the burden of this widespread disease. Recent research findings and advances clinical practice in the field are reported and analyzed by international experts. The journal presents this information in clear, accessible formats. All articles are subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal’s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3. Coverage includes: Diagnosis and imaging, Surgical approaches, Radiotherapy, Systemic therapies, Cancer clinical trials, Genetic aspects of disease, Personalized medicine, Translational research and biomarker studies, Management of psychological distress, Epidemiological studies, Pharmacoeconomics, Evidence-based treatment guidelines.